Of note, pharmacological inhibitors of glucosylceramide synthase (GCS), the enzyme which glycosylates ceramide to produce GlcCer, have been shown to reduce glycosphingolipid accumulation and improve associated pathologies in neuropathic Gaucher disease mouse models27–29. The gene discussed is UGCG; the disease is Gaucher disease.